用户头像
阿笨猫先生
 · 江苏  

回复@LGNLM: our conversation focused on the differentiation in the competitive landscape。
大摩的看法是当下对于亚盛的竞争格局非最优,不具备绝对的领先优势,但差异化的竞争格局优势可以去获取。这就是阿笨昨天说的,亚盛需要天王山一战去奠定自身地位,让竞争格局更加清晰和友好化。
we believe AAPG is making good headway in bringing both programs to the global stage. Clearly, both carry unique attributes in their respective target indications. We continue to believe the approach and differentiation wil

@进宝招财君 :$亚盛医药-B(06855)$
贴一个大摩在Ash对亚盛的交流跟踪:
We hosted mgmt for a group breakfast at ASH yesterday. With olverembatinib (OLV) and lisaftoclax (LIS) launched in China, we believe AAPG is making good headway in bringing both programs to the global stage. Clear...
点击查看全文